Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-379 vs Co-administration of D759, D745, and D150 in Healthy Subjects
NCT05719155Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Feb 2023
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-379 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Measurable Concentration. Started Feb 2023; status: completed.
02
Drugs
CKD-379
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05719155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719155.